Ryan Deschner
Stock Analyst at Raymond James
(4.75)
# 114
Out of 4,944 analysts
17
Total ratings
86.67%
Success rate
32.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $25.20 | +62.70% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $7.60 | +255.26% | 3 | Aug 8, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $54 | $44.64 | +20.97% | 1 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $5.75 | +108.70% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $26.58 | +88.11% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $41.27 | +195.61% | 1 | Jul 24, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $62 | $24.05 | +157.80% | 1 | Jul 14, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $15.82 | +76.99% | 3 | Jan 14, 2025 |
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $25.20
Upside: +62.70%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $7.60
Upside: +255.26%
Palvella Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $54
Current: $44.64
Upside: +20.97%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $5.75
Upside: +108.70%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $26.58
Upside: +88.11%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $41.27
Upside: +195.61%
Tvardi Therapeutics
Jul 14, 2025
Initiates: Outperform
Price Target: $62
Current: $24.05
Upside: +157.80%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $15.82
Upside: +76.99%